Cor Therapeutics Inc. (CORR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Phil Cressman who wrote (190)	4/2/1998 10:40:00 AM
From: JW@KSC	Read Replies (1) of 712

Here's the news I'm sure many are feeling much better this morning. JW@KSC SOUTH SAN FRANCISCO, Calif.--(BW)--April 2, 1998--COR Therapeutics, Inc. (Nasdaq: CORR) announced today that it has received a letter from the U.S. Food and Drug Administration (FDA) stating that INTEGRILIN(TM) (eptifibatide) is approvable for the treatment of patients with acute coronary syndromes and as an adjunct to percutaneous transluminal coronary angioplasty or atherectomy (PTCA). Acute coronary syndromes include unstable angina and non-Q-wave myocardial infarction. The FDA's letter states that INTEGRILIN(TM) may be approved upon the satisfactory completion of product labeling and response to the agency's outstanding issues. The FDA letter proposes a dosage of 180 ug/kg bolus + 2 ug/kg/min infusion for patients with acute coronary syndromes and a dosage of 135 ug/kg bolus + 0.5 ug/kg/min when used as an adjunct to PTCA. INTEGRILIN(TM) is a parenteral GP IIb-IIIa inhibitor that has been shown to block platelet aggregation, a crucial event in thrombus formation in coronary arteries. COR and Schering-Plough Corporation are worldwide partners for INTEGRILIN(TM). FULL TEXT at businesswire.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next